Centre National De La Recherche Scientifique

Assistance Publique-Hopitaux De Paris

Université Paris Diderot-Paris 7

Université Paris—sud

Université De Reims Champagne-Ardenne

Université Paris-Saclay

Centre National De La Recherche Scientifique-Cnrs

Kevin Cariou

Robert H Dodd

Thierry Naas

Bogdan Iorga

Clement Denhez

Eugénie Romero

Mohamed Benchekroun

Saoussen Oueslati

Corinne Minard

Bogdan-Iuliu Iorga

Robert Dobb

Stephanie Gourdain

Jean Maurice Delabar

Nathalie Janel

Fernando Rodrigues Lima

Julien Dairou

Robert Dodd

The present application relates to novel 3-imidazolines of formula (I') and (I) below: (I&#x2032;) (I) Wherein Ar, Ar, Ar, and Rto Rare as defined in the claims. The 3-imidazolines of the invention are useful in antibiotic therapies, in particular as inhibitors of carbapenemases. They are also useful as antibiotics themselves. The present invention also concerns a method for preparing more specifically the 3-imidazolines of formula (I). The present invention further relates to conjugates of said compounds with known antibiotics. 

2- or 3-imidazolines as carbapenemases inhibitors

The present application relates to novel azetidinimine of formula (I). Wherein R-Rare as defined in claim. The azetidinimine of the invention are useful as antibiotics and as inhibitors of a carbapenemases. The present invention thus further relates to their use in antibiotic therapies and their methods of synthesis. 

Azetidinimines as carbapenemases inhibitors

The present invention discloses compositions of novel DYRK1A protein inhibitors based on a 3,5-diarylazaindole motif and their preparation and use as medications in the treatment of cognitive disorders associated with dysfunction of DYRK1A protein, with Down's syndrome and with Alzheimer's disease. 

3,5-diarylazaindoles as DYRK1A protein inhibitors for the treatment of cognitive deficiencies associated with Down's syndrome and with Alzheimer's disease

Growing community of inventors

Paris, France

Kevin Cariou